7 Ottobre 2026

leukemia

Leucemia linfatica cronica (LLC): AIFA approva la rimborsabilita’ in Italia di pirtobrutinib di Lilly tralokinumab, approvazione, aifa, italia, rimborsabilità, leo pharma, dermatite atopica, terapia, adolescenti, Belloni Fortina,, calcineurina, pozzolini, mani, viso, penna, lesioni,

Leucemia linfatica cronica (LLC): AIFA approva la rimborsabilita’ in Italia di pirtobrutinib di Lilly

Redazione 7 Maggio 2026
Lilly annuncia che l’Agenzia Italiana del Farmaco (AIFA) ha approvato la rimborsabilità di pirtobrutinib per il trattamento...
Per saperne di più Maggiori informazioni su Leucemia linfatica cronica (LLC): AIFA approva la rimborsabilita’ in Italia di pirtobrutinib di Lilly
Study Shows Duvelisib Has Marked Response, Survival Benefit in Difficult-to-Treat Leukemia and Lymphoma Compared with Standard Therapy

Study Shows Duvelisib Has Marked Response, Survival Benefit in Difficult-to-Treat Leukemia and Lymphoma Compared with Standard Therapy

Redazione 7 Ottobre 2018
For some patients with difficult-to-treat leukemia and lymphoma, the investigational oral medicine duvelisib may significantly improve disease...
Per saperne di più Maggiori informazioni su Study Shows Duvelisib Has Marked Response, Survival Benefit in Difficult-to-Treat Leukemia and Lymphoma Compared with Standard Therapy
Acute myeloid leukemia: Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyo’ s Quizartinib Significantly Prolongs Overall Survival as Single Agent Compared to Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations #EHA23

Acute myeloid leukemia: Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyo’ s Quizartinib Significantly Prolongs Overall Survival as Single Agent Compared to Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations #EHA23

Redazione 16 Giugno 2018
Daiichi Sankyo Company, Limited announced that positive results from the pivotal QuANTUM-R phase 3 study of single...
Per saperne di più Maggiori informazioni su Acute myeloid leukemia: Phase 3 QuANTUM-R Study Demonstrates Daiichi Sankyo’ s Quizartinib Significantly Prolongs Overall Survival as Single Agent Compared to Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations #EHA23
ASH President Comments on FDA Approval of First CART-Cell Therapy to Treat Childhood Leukemia

ASH President Comments on FDA Approval of First CART-Cell Therapy to Treat Childhood Leukemia

Redazione 30 Agosto 2017
Today the U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor (CAR) T-cell therapy...
Per saperne di più Maggiori informazioni su ASH President Comments on FDA Approval of First CART-Cell Therapy to Treat Childhood Leukemia